>8 g/L titres in the high-expression CHO platform
Process intensification across the upstream workflow pushed fed-batch antibody titres beyond 8 g/L while maintaining clone stability over 60 generations.
Read more →Protein & antibody expression
From sequence to scalable expression.
ImmunovaTx is a specialist cell-line development and expression partner. We take your gene or sequence to a stable, high-yielding, manufacturable production cell line and a scalable process — high titres that move a biologic from discovery to the clinic faster, with a clean regulatory story.
01
The challenge
Most biologics stall before they ever scale
Taking a sequence to a reproducible cGMP process is where many programmes lose time. Low titres limit the clinical supply you can afford; an unstable cell line drifts before you reach the clinic; and a poorly characterised lineage leaves a weak manufacturability and regulatory story. We build the cell line and process that scale cleanly, the first time.
02
Expression toolbox
The right expression system for each molecule
| System | Best suited to | Coverage |
|---|---|---|
| Stable CHO platformMetabolic-selection mammalian · high, stable titres | mAbs, bispecifics, complex proteins | |
| Transposon-based stable poolsRapid representative material · speed to clinic | Early candidate & tox supply |
03
Why ImmunovaTx
A focused partner, not a black box.
i
High titres
Our high-expression CHO platform and clone-selection workflow are tuned for yield — delivering the grams per litre that make clinical and commercial supply affordable.
ii
Speed to clinic
Transposon-based stable pools generate representative material in weeks, so your team can run tox and candidate selection while the final clonal line is being locked down.
iii
Regulatory-ready lineage
Documented clonal derivation, monoclonality assurance and a full cell-line history give you a manufacturable line with a clean regulatory and CMC narrative.
04
Latest news
What's new at ImmunovaTx
Stable pool delivers GMP-representative material in 6 weeks
A transposon-based stable pool supplied gram-scale, representative bispecific material for a partner's tox programme weeks ahead of the conventional route.
Read more →Expanded single-cell cloning and clonality assurance
New imaging-based single-cell cloning strengthens our monoclonality evidence package and shortens the path to a documented, regulatory-ready clonal line.
Read more →Have a sequence that needs to express and scale?
Send us your molecule format and target profile. We'll tell you candidly which expression system fits and how fast we can get you manufacturable material.